Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 3/2014

01.09.2014 | Original Research

Rectal Versus Non-rectal Primary Signet Ring Cell Carcinoma of the Colorectum: a Retrospective Survival Analysis Controlled for Confounders

verfasst von: Andrea Ciarrocchi

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Our objective was to compare the outcomes of rectal and non-rectal primary signet ring cell adenocarcinoma of the colorectum.

Methods

A retrospective survival analysis was performed using the Surveillance, Epidemiology, and End Results Program database between 2004 and 2009 on subjects who were diagnosed as having a primary signet ring cell carcinoma of the colorectum. Cox proportional hazard regression analysis controlled for confounders was used to assess overall survival comparing rectal and non-rectal cancers.

Results

Our population was composed of 1,484 patients: 200 affected by rectal cancer and 1,284 by non-rectal cancer. Unadjusted survival curves resulted to be almost superimposable (P = 0.916). After controlling for age, gender, race, tumor stage, grade, and size, tumor location demonstrated a statistically significant impact on overall survival (P = 0.032; 95 % confidence interval 0.640–0.980; hazard ratio 0.792).

Conclusion

On the basis of analysis of information from the SEER database, the signet ring cell carcinoma of the rectum was associated to a worse prognosis as compared to non-rectal cancer.
Literatur
1.
Zurück zum Zitat Bittorf B, Merkel S, Matzel KE, Wein A, Dimmler A, Hohenberger W. Primary signet-ring cell carcinoma of the colorectum. Langenbecks Arch Surg. 2004;389(3):178–83.PubMedCrossRef Bittorf B, Merkel S, Matzel KE, Wein A, Dimmler A, Hohenberger W. Primary signet-ring cell carcinoma of the colorectum. Langenbecks Arch Surg. 2004;389(3):178–83.PubMedCrossRef
2.
Zurück zum Zitat Chen JS, Hsieh PS, Hung SY, Tang R, et al. Clinical significance of signet ring cell rectal carcinoma. Int J Colorectal Dis. 2004;19(2):102–7.PubMed Chen JS, Hsieh PS, Hung SY, Tang R, et al. Clinical significance of signet ring cell rectal carcinoma. Int J Colorectal Dis. 2004;19(2):102–7.PubMed
3.
Zurück zum Zitat Connelly JH, Robey-Cafferty SS, Naggar AK, Cleary KR. Exophytic signet-ring cell carcinoma of the colorectum. Arch Pathol Lab Med. 1991;115(2):134–6.PubMed Connelly JH, Robey-Cafferty SS, Naggar AK, Cleary KR. Exophytic signet-ring cell carcinoma of the colorectum. Arch Pathol Lab Med. 1991;115(2):134–6.PubMed
4.
Zurück zum Zitat Green JB, Timmcke AE, Mitchell WT, Hicks TC, Gathright Jr JB, Ray JE. Mucinous carcinoma—just another colon cancer? Dis Colon Rectum. 1993;36(1):49–54.PubMedCrossRef Green JB, Timmcke AE, Mitchell WT, Hicks TC, Gathright Jr JB, Ray JE. Mucinous carcinoma—just another colon cancer? Dis Colon Rectum. 1993;36(1):49–54.PubMedCrossRef
5.
Zurück zum Zitat Kang H, O’Connell JB, Maggard MA, Sack J, Ko CY. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum. 2005;115(2):1161–8.CrossRef Kang H, O’Connell JB, Maggard MA, Sack J, Ko CY. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum. 2005;115(2):1161–8.CrossRef
6.
Zurück zum Zitat Messerini L, Palomba A, Zampi G. Primary signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum. 1995;38(11):1189–92.PubMedCrossRef Messerini L, Palomba A, Zampi G. Primary signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum. 1995;38(11):1189–92.PubMedCrossRef
7.
Zurück zum Zitat Nissan A, Guillem JG, Paty PB, Wong WD, Cohen AM. Signet-ring cell carcinoma of the colon and rectum: a matched control study. Dis Colon Rectum. 1999;42(9):1176–80.PubMedCrossRef Nissan A, Guillem JG, Paty PB, Wong WD, Cohen AM. Signet-ring cell carcinoma of the colon and rectum: a matched control study. Dis Colon Rectum. 1999;42(9):1176–80.PubMedCrossRef
8.
Zurück zum Zitat Fardeli R, Campora E, Lapertosa E, Gentile G, Zoli R, Prior S, et al. Primary mucinous adenocarcinoma and signet ring cell carcinoma of colon and rectum. Oncology. 1994;51(1):1214–21. Fardeli R, Campora E, Lapertosa E, Gentile G, Zoli R, Prior S, et al. Primary mucinous adenocarcinoma and signet ring cell carcinoma of colon and rectum. Oncology. 1994;51(1):1214–21.
9.
Zurück zum Zitat Psathakis D, Schiedeck TH, Krug F, Oevermann E, et al. Ordinary colorectal adenocarcinoma vs primary colorectal signet-ring cell carcinoma: study matched for age, gender, grade and stage. Dis Colon Rectum. 1999;42(12):1618–25.PubMedCrossRef Psathakis D, Schiedeck TH, Krug F, Oevermann E, et al. Ordinary colorectal adenocarcinoma vs primary colorectal signet-ring cell carcinoma: study matched for age, gender, grade and stage. Dis Colon Rectum. 1999;42(12):1618–25.PubMedCrossRef
10.
Zurück zum Zitat Surveillance, Epidemiology, and End Results (SEER) Program (2002) Public use data (1973–1999). Cancer Statistics Branch, Surveillance Research Program, DCCPS. [Online] http://www.seer.cancer.gov. Surveillance, Epidemiology, and End Results (SEER) Program (2002) Public use data (1973–1999). Cancer Statistics Branch, Surveillance Research Program, DCCPS. [Online] http://​www.​seer.​cancer.​gov.
13.
Zurück zum Zitat Pande R, Sunga A, Levea C, Wilding GE, Bshara W, Reid M, et al. Significance of signet-ring cells in patients with colorectal cancer. Dis Colon Rectum. 2008;51:50–5.PubMedCrossRef Pande R, Sunga A, Levea C, Wilding GE, Bshara W, Reid M, et al. Significance of signet-ring cells in patients with colorectal cancer. Dis Colon Rectum. 2008;51:50–5.PubMedCrossRef
14.
Zurück zum Zitat Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol. 2006;19(1):59–68.PubMedCrossRef Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol. 2006;19(1):59–68.PubMedCrossRef
15.
Zurück zum Zitat Robey-Cafferty SS, Naggar AK, Cleary KR, Connelly JH. Exophytic signet-ring cell carcinoma of the colorectum. Arch Pathol Lab Med. 1992;115(2):134–6. Robey-Cafferty SS, Naggar AK, Cleary KR, Connelly JH. Exophytic signet-ring cell carcinoma of the colorectum. Arch Pathol Lab Med. 1992;115(2):134–6.
16.
Zurück zum Zitat Aste H, Baracchini P, Conio M, Fulcheri E, et al. Primary signet-ring carcinoma of the large bowel. Report of nine cases. Cancer. 1985;56(11):2723–6.PubMedCrossRef Aste H, Baracchini P, Conio M, Fulcheri E, et al. Primary signet-ring carcinoma of the large bowel. Report of nine cases. Cancer. 1985;56(11):2723–6.PubMedCrossRef
17.
Zurück zum Zitat Song W, Wu SJ, He YL, Cai SR, et al. Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or non-mucinous adenocarcinoma: experience at an institution in southern China. Chin Med J (Engl). 2009;122(13):1486–91. Song W, Wu SJ, He YL, Cai SR, et al. Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or non-mucinous adenocarcinoma: experience at an institution in southern China. Chin Med J (Engl). 2009;122(13):1486–91.
18.
Zurück zum Zitat Grillo-Ruggieri F, Mantello G, Berardi R, Cardinali M, et al. Mucinous rectal adenocarcinoma can be associated to tumor downstaging after preoperative chemoradiotherapy. Dis Colon Rectum. 2007;50(10):1594–603.PubMedCrossRef Grillo-Ruggieri F, Mantello G, Berardi R, Cardinali M, et al. Mucinous rectal adenocarcinoma can be associated to tumor downstaging after preoperative chemoradiotherapy. Dis Colon Rectum. 2007;50(10):1594–603.PubMedCrossRef
19.
Zurück zum Zitat Box B, Lindsey I, Wheeler JM, Warren BF, et al. Neoadjuvant therapy for rectal cancer: improved tumor response, local recurrence, and overall survival in nonanemic patients. Dis Colon Rectum. 2005;122(13):1486–91. Box B, Lindsey I, Wheeler JM, Warren BF, et al. Neoadjuvant therapy for rectal cancer: improved tumor response, local recurrence, and overall survival in nonanemic patients. Dis Colon Rectum. 2005;122(13):1486–91.
20.
Zurück zum Zitat Symonds DA, Vickery AL. Mucinous carcinoma of the colon and rectum. Cancer. 1976;37(4):1981–00.CrossRef Symonds DA, Vickery AL. Mucinous carcinoma of the colon and rectum. Cancer. 1976;37(4):1981–00.CrossRef
21.
Zurück zum Zitat Hyngstrom JR, Hu C-Y, Xing Y, You YN, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol. 2012;19(9):2814–21.PubMedCentralPubMedCrossRef Hyngstrom JR, Hu C-Y, Xing Y, You YN, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol. 2012;19(9):2814–21.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Min BS, Kim NK, Ko YT, Baek SH, et al. Clinicopathological features of signet-ring cell carcinoma of the colon and rectum: a case-matched study. Hepatogastroenterology. 2009;56(93):984–8.PubMed Min BS, Kim NK, Ko YT, Baek SH, et al. Clinicopathological features of signet-ring cell carcinoma of the colon and rectum: a case-matched study. Hepatogastroenterology. 2009;56(93):984–8.PubMed
23.
Zurück zum Zitat Shin US, Yu CS, Kim JH, et al. Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis. Ann Surg Oncol. 2011;18(8):2232–9.PubMedCrossRef Shin US, Yu CS, Kim JH, et al. Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis. Ann Surg Oncol. 2011;18(8):2232–9.PubMedCrossRef
Metadaten
Titel
Rectal Versus Non-rectal Primary Signet Ring Cell Carcinoma of the Colorectum: a Retrospective Survival Analysis Controlled for Confounders
verfasst von
Andrea Ciarrocchi
Publikationsdatum
01.09.2014
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 3/2014
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-014-9604-0

Weitere Artikel der Ausgabe 3/2014

Journal of Gastrointestinal Cancer 3/2014 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.